A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

Trial Profile

A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Docetaxel (Primary) ; Vorinostat (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2010 Actual initiation date changed from Nov 2008 to Sep 2009 as reported by ClinicalTrials.gov.
    • 19 Nov 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top